Two groundbreaking medical studies have revealed the potential to improve the effectiveness of cancer treatment and reduce its debilitating side effects through an innovative technique based on fecal microbiota transplantation, or fecal metastasis (FMT).
The results, published in the prestigious journal Nature Medicine, show how this unconventional approach could revolutionize the treatment of several types of malignant tumors by enhancing the patient's immune response and reducing the toxic burden of current treatments.
In the first study, which focused on patients with advanced kidney cancer, researchers tested the safety and efficacy of combining FMT capsules with standard immunotherapy. They found that these customized capsules significantly helped alleviate toxic side effects, particularly colitis and severe diarrhea, which often force patients to prematurely discontinue life-saving treatment.
This is an important advance, as allowing patients to complete their full courses of treatment without severe suffering can greatly improve their clinical outcomes and quality of life.
The second study, which included patients with lung cancer and melanoma, yielded even more remarkable results. After receiving FMT treatment, 80% of lung cancer patients responded to immunotherapy, compared to only 39-45% of those receiving immunotherapy alone.
Bad body odor may be a subtle sign of cancer
Bad body odor may be a subtle sign of cancer
75% of melanoma patients showed a positive response after combining the two treatments, compared to 50-58% in the group that received only conventional immunotherapy.
This research utilizes advanced FMT capsules (known as LND101), developed at the Lawson Research Institute in London, Ontario, and produced from the stool of healthy donors. The goal of these capsules is to restore a healthy balance to the patient's gut microbiome, creating a more favorable internal environment for fighting malignant tumors.
